COVID-19 (Coronavirus)

Fatty Liver Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for fatty liver. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your fatty liver condition.

Questions? See the Clinical Trials FAQs.

Nonalcoholic Fatty Liver Disease (NAFLD)

Condition: 

Nonalcoholic fatty liver disease (NAFLD), liver disease

Participant Requirements:

  • Patients suspected of nonalcoholic fatty liver disease (NAFLD)
  • At least 18 years old
  • Patients scheduled for liver biopsy due to suspicion of NASH are eligible
  • Blood must be drawn within 60 days of liver biopsy

Summary:

This study focuses on individuals who have may have nonalcoholic fatty liver disease (NAFLD). The purpose of the study is to evaluate blood samples and tissue to discover and develop laboratory tests that can detect liver disease, as well as predict and monitor response to treatment.

Nonalcoholic Steatohepatitis (NASH)

Condition:

Nonalcoholic steatohepatitis (NASH), cirrhosis

Key Inclusion Criteria:

  • 18-75 years old
  • Evidence of portal hypertension
  • History confirming NASH cirrhosis

Summary:

This study focuses on individuals who may have nonalcoholic steatohepatitis (NASH) cirrhosis (scarring of the liver due to fatty liver disease and inflammation) and have not yet developed any complications of cirrhosis. The purpose of the study is to determine the safety and efficacy of an investigational drug called belapectin (GR-MD-02) for the prevention of esophageal varices (enlarged veins in the esophagus) in NASH cirrhosis.

Condition:

Nonalcoholic Steatohepatitis

Key Inclusion Criteria:

  • 18-75 years old
  • Confirmation of steatohepatitis on a diagnostic liver biopsy
  • Fibrosis Stage 1 or greater and below Stage 4 (according to the NASH Clinical Research Network fibrosis staging system)
  • Body mass index ≤45 kg/m²

Summary:

This study focuses on patients diagnosed with nonalcoholic steatohepatitis (NASH) with fibrosis (recently confirmed by a liver biopsy) or those who are at high risk of having this disease and are willing to undergo a liver biopsy to determine whether they have NASH with fibrosis. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug called elafibranor in these patients. Researchers will assess the efficacy of elafibranor compared to placebo (inactive substance) for the treatment of NASH. The study will also evaluate whether elafibranor reduces the number of patients that will develop further complications from NASH, such as liver cirrhosis.

Condition:

Nonalcoholic steatohepatitis

Participant Requirements:

  • 18-75 years old
  • Confirmation of nonalcoholic steatohepatitis (NASH) on a diagnostic liver biopsy
  • Total NAFLD Activity Score of four or more with at least one in each component of the NAS score

Summary:

This study focuses on individuals diagnosed with nonalcoholic steatohepatitis (NASH) who are overweight or obese and who have prediabetes or Type 2 diabetes. NASH is a chronic liver disease that may cause scarring of the liver and liver failure. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug called aramchol on NASH and NASH-related complications compared to placebo (inactive substance).

Condition: 

Nonalcoholic steatohepatitis (NASH), fibrosis

Participant Requirements:

  • At least 18 years old
  • Suspected or confirmed diagnosis of nonalcoholic steatohepatitis (NASH) fibrosis
  • Not pregnant or breastfeeding

Summary:

The purpose of this study is to evaluate the effects of an investigational drug called MGL-3196 on individuals with nonalcoholic steatohepatitis (NASH). Researchers aim to determine the safety, effectiveness and optimal dosage of MGL-3196, as well as whether treatment with MGL-3196 for several years will benefit participants.

Condition: 

Nonalcoholic steatohepatitis, fibrosis

Participant Requirements:

  • Between 18-75 years old (or the minimum country-specific age of consent if >18)
  • BMI ≥25 kg/m2 (in Africa, Europe, North/South America) or ≥22.5 kg/m2 (in Asia)
  • Ultrasound-guided liver biopsy meeting the NASH Clinical Research Network definition 

Summary:

This study focuses on individuals who may have an abnormally high amount of fat and swelling (inflammation) of the liver along with some fibrosis (scarring) that is not related to excessive alcohol consumption. The purpose of the study is to determine whether the investigational drugs PF-06865571 and PF-05221304 (PF-06865571 alone or when given together with PF-05221304) improve nonalcoholic steatohepatitis (NASH) with liver fibrosis compared to placebo (inactive substance).

Condition:

Nonalcoholic steatohepatitis

Participant Requirements:

  • Confirmed diagnosis of nonalcoholic steatohepatitis
  • 18-75 years old
  • Screening MRI-PDFF with ≥8% liver fat fraction

Summary:

The purpose of this study is to determine the safety and effectiveness of an investigational thyroid hormone receptor drug called VK2809 for the treatment of nonalcoholic steatohepatitis (NASH). VK2809 is designed to reduce cholesterol and lower liver fat content.